pharmaphorum January 19, 2022
According to Rock Health’s annual digital health funding report, US-based digital health companies enabling life sciences research and development raised $5.8 billion (£4.3 billion) in 2021, making it the top funded category of the sector.
This is the first time R&D has topped the chart since Rock Health began tracking US digital health funding in 2011, although it nabbed the number two slot in 2018 and 2020.
The San Francisco-based research firm attributed the category’s over-performance to COVID-19’s acting as a forcing function for the digitisation of key pharma processes.
“In 2021, digital health companies catalysing R&D in biopharma and medtech topped the chart with $5.8B in funding, stimulated by the COVID-accelerated adoption of real-world evidence and decentralized trials,” authors...